T. Rowe Price Associates
ADCT icon

T. Rowe Price Associates’s ADC Therapeutics ADCT Stock Holding History

T. Rowe Price Associates’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81K Buy
74,860
+4,813
+7% +$14K ﹤0.01% 3166
2026
Q1 		$263K Buy
70,047
+23,297
+50% +$91.8K ﹤0.01% 2741
2025
Q4 		$166K Buy
46,750
+9,537
+26% +$38.7K ﹤0.01% 2850
2025
Q3 		$149K Hold
37,213
– – ﹤0.01% 2850
2025
Q2 		$100K Buy
37,213
+1,002
+3% +$2.11K ﹤0.01% 2890
2025
Q1 		$52K Buy
36,211
+7,380
+26% +$12.5K ﹤0.01% 2921
2024
Q4 		$58K Hold
28,831
– – ﹤0.01% 2915
2024
Q3 		$91K Buy
28,831
+6,355
+28% +$20K ﹤0.01% 2836
2024
Q2 		$0 Buy
+22,476
New +$89.3K ﹤0.01% 2924
2023
Q3 		– Sell
-1,221,838
Closed -$2.63M – 2891
2023
Q2 		$2.63M Sell
1,221,838
-84,600
-6% -$190K ﹤0.01% 1382
2023
Q1 		$2.55M Sell
1,306,438
-180,867
-12% -$667K ﹤0.01% 1383
2022
Q4 		$5.71M Buy
1,487,305
+296,551
+25% +$1.19M ﹤0.01% 1162
2022
Q3 		$5.74M Sell
1,190,754
-770,456
-39% -$5.58M ﹤0.01% 1173
2022
Q2 		$15.6M Sell
1,961,210
-501,426
-20% -$4.74M ﹤0.01% 1232
2022
Q1 		$36.2M Sell
2,462,636
-388,801
-14% -$6.17M ﹤0.01% 1072
2021
Q4 		$57.6M Buy
2,851,437
+22,697
+0.8% +$547K 0.01% 952
2021
Q3 		$76.8M Buy
2,828,740
+166,155
+6% +$4.26M 0.01% 859
2021
Q2 		$64.8M Sell
2,662,585
-83,209
-3% -$1.93M 0.01% 941
2021
Q1 		$67M Buy
2,745,794
+780,033
+40% +$22.6M 0.01% 893
2020
Q4 		$62.9M Buy
1,965,761
+1,246,586
+173% +$40.9M 0.01% 874
2020
Q3 		$23.7M Buy
719,175
+126,924
+21% +$5.49M ﹤0.01% 1109
2020
Q2 		$27.7M Buy
+592,251
New +$22.5M ﹤0.01% 1043

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates's ADCT Position: Q2 2026 in Review

T. Rowe Price Associates increased its ADC Therapeutics (ADCT) stake by 6.9% in Q2 2026, buying an estimated $14K and bringing the position to 74,860 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

T. Rowe Price Associates first reported a position in ADCT in Q2 2020 and has held it in 22 quarters since. The position peaked at $76.8M in Q3 2021. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • T. Rowe Price Associates held 74,860 shares of ADC Therapeutics worth $81K as of Q2 2026.
  • T. Rowe Price Associates bought 4,813 ADC Therapeutics shares in Q2 2026, an estimated $14K.
  • ADC Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3166 holding.
  • T. Rowe Price Associates first reported a position in ADC Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • T. Rowe Price Associates's ADC Therapeutics position peaked at $76.8M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.